{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:15:09Z","timestamp":1790612109168,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s12325-025-03418-x","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T07:12:00Z","timestamp":1764054720000},"page":"304-316","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin\/Kexin Type 9 Inhibitors: A Systematic Review and Meta-Analysis"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5620-6468","authenticated-orcid":false,"given":"Walter","family":"Masson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1377-7313","authenticated-orcid":false,"given":"Mart\u00edn","family":"Lobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1913-0310","authenticated-orcid":false,"given":"Gustavo","family":"Giunta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3694-1083","authenticated-orcid":false,"given":"Leandro","family":"Barbagelata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8764-4700","authenticated-orcid":false,"given":"Juan P.","family":"Nogueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"issue":"5","key":"3418_CR1","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1097\/MOL.0000000000000997","volume":"36","author":"K \u00d6\u00f6rni","year":"2025","unstructured":"\u00d6\u00f6rni K, Lorey MB. Beyond cholesterol: linking the conformation of apolipoprotein B to atherogenesis. Curr Opin Lipidol. 2025;36(5):226\u201331. https:\/\/doi.org\/10.1097\/MOL.0000000000000997.","journal-title":"Curr Opin Lipidol"},{"issue":"32","key":"3418_CR2","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","volume":"38","author":"BA Ference","year":"2017","unstructured":"Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459\u201372. https:\/\/doi.org\/10.1093\/eurheartj\/ehx144.","journal-title":"Eur Heart J"},{"key":"3418_CR3","doi-asserted-by":"publisher","first-page":"ehaf190","DOI":"10.1093\/eurheartj\/ehaf190","volume":"29","author":"F Mach","year":"2025","unstructured":"Mach F, Koskinas KC, Roeters van Lennep JE, et al. 2025 Focused Update of the 2019 ESC\/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2025;29:ehaf190. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf190.","journal-title":"Eur Heart J."},{"key":"3418_CR4","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1615664.","journal-title":"N Engl J Med"},{"key":"3418_CR5","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379:2097\u2013107. https:\/\/doi.org\/10.1056\/NEJMoa1801174.","journal-title":"N Engl J Med"},{"issue":"16","key":"3418_CR6","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","volume":"382","author":"KK Ray","year":"2020","unstructured":"Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507\u201319. https:\/\/doi.org\/10.1056\/NEJMoa1912387.","journal-title":"N Engl J Med"},{"issue":"59","key":"3418_CR7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.athplu.2024.11.003","volume":"12","author":"N Ferri","year":"2024","unstructured":"Ferri N, Marodin G. Emerging oral therapeutic strategies for inhibiting PCSK9. Atheroscler Plus. 2024;12(59):25\u201331. https:\/\/doi.org\/10.1016\/j.athplu.2024.11.003.","journal-title":"Atheroscler Plus"},{"issue":"16","key":"3418_CR8","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1016\/j.jacc.2023.02.018","volume":"81","author":"CM Ballantyne","year":"2023","unstructured":"Ballantyne CM, Banka P, Mendez G, et al. Phase 2b randomized trial of the oral PCSK9 inhibitor MK-0616. J Am Coll Cardiol. 2023;81(16):1553\u201364. https:\/\/doi.org\/10.1016\/j.jacc.2023.02.018.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"3418_CR9","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/S2213-8587(23)00325-X","volume":"12","author":"MJ Koren","year":"2024","unstructured":"Koren MJ, Descamps O, Hata Y, et al. PCSK9 inhibition with orally administered NNC0385-0434 in hypercholesterolaemia: a randomised, double-blind, placebo-controlled and active-controlled phase 2 trial. Lancet Diabetes Endocrinol. 2024;12(3):174\u201383. https:\/\/doi.org\/10.1016\/S2213-8587(23)00325-X.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"21","key":"3418_CR10","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1016\/j.jacc.2025.03.499","volume":"85","author":"MJ Koren","year":"2025","unstructured":"Koren MJ, Vega RB, Agrawal N, et al. An oral PCSK9 inhibitor for treatment of hypercholesterolemia: the PURSUIT randomized trial. J Am Coll Cardiol. 2025;85(21):1996\u20132007. https:\/\/doi.org\/10.1016\/j.jacc.2025.03.499.","journal-title":"J Am Coll Cardiol"},{"key":"3418_CR11","doi-asserted-by":"publisher","first-page":"118514","DOI":"10.1016\/j.atherosclerosis.2024.118514","volume":"395","author":"R Vega","year":"2024","unstructured":"Vega R, Garkaviy P, Knochel J, et al. AZD0780, the first oral small molecule PCSK9 inhibitor for the treatment of hypercholesterolemia: Results from a randomized, single-blind, placebo-controlled phase 1 trial. Atherosclerosis. 2024;395:118514. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2024.118514.","journal-title":"Atherosclerosis."},{"issue":"5","key":"3418_CR12","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.cmet.2022.03.006","volume":"34","author":"J Wang","year":"2022","unstructured":"Wang J, Zhao J, Yan C, et al. Identification and evaluation of a lipid-lowering small compound in preclinical models and in a phase I trial. Cell Metab. 2022;34(5):667-680.e6. https:\/\/doi.org\/10.1016\/j.cmet.2022.03.006.","journal-title":"Cell Metab"},{"key":"3418_CR13","doi-asserted-by":"publisher","DOI":"10.1161\/circ.142.suppl_3.1257","author":"J Liu","year":"2020","unstructured":"Liu J, Jiang B, Zhao S, et al. Abstract 12579: CVI-LM001, a first-in-class novel oral PCSK9 modulator, lowers plasma LDL-c and reduces circulating PCSK9 in preclinical animal models and in hyperlipidemic human subjects. Circulation. 2020. https:\/\/doi.org\/10.1161\/circ.142.suppl_3.1257.","journal-title":"Circulation"},{"issue":"2","key":"3418_CR14","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1161\/CIRCULATIONAHA.122.063372","volume":"148","author":"DG Johns","year":"2023","unstructured":"Johns DG, Campeau LC, Banka P, et al. Orally bioavailable macrocyclic peptide that inhibits binding of PCSK9 to the low density lipoprotein receptor. Circulation. 2023;148(2):144\u201358. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.063372.","journal-title":"Circulation"},{"key":"3418_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n7","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Br Med J. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n7.","journal-title":"Br Med J"},{"key":"3418_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"28","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovic J, Page MJ, et al. Rob 2: a revised tool for assessing risk of bias in randomised trials. Br Med J. 2019;28:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"Br Med J"},{"key":"3418_CR17","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol. 2014;14:135. https:\/\/doi.org\/10.1186\/1471-2288-14-135.","journal-title":"BMC Med Res Methodol"},{"key":"3418_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v036.i03","volume":"36","author":"W Viechtbauer","year":"2010","unstructured":"Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Soft. 2010;36:1\u201348. https:\/\/doi.org\/10.18637\/jss.v036.i03.","journal-title":"J Stat Soft"},{"issue":"6","key":"3418_CR19","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1038\/s44161-022-00085-x","volume":"1","author":"P Libby","year":"2022","unstructured":"Libby P, Tokg\u00f6zo\u011flu L. Chasing LDL cholesterol to the bottom\u2014PCSK9 in perspective. Nat Cardiovasc Res. 2022;1(6):554\u201361. https:\/\/doi.org\/10.1038\/s44161-022-00085-x.","journal-title":"Nat Cardiovasc Res"},{"key":"3418_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/10742484221100107","volume":"27","author":"C Coppinger","year":"2022","unstructured":"Coppinger C, Movahed MR, Azemawah V, Peyton L, Gregory J, Hashemzadeh MA. Comprehensive review of PCSK9 inhibitors. J Cardiovasc Pharmacol Ther. 2022;27:1\u201314. https:\/\/doi.org\/10.1177\/10742484221100107.","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"9","key":"3418_CR21","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1001\/jamacardio.2024.1659","volume":"9","author":"EQ Klug","year":"2024","unstructured":"Klug EQ, Llerena S, Burgess LJ, et al. Efficacy and safety of lerodalcibep in patients with or at high risk of cardiovascular disease: a randomized clinical trial. JAMA Cardiol. 2024;9(9):800\u20137. https:\/\/doi.org\/10.1001\/jamacardio.2024.1659.","journal-title":"JAMA Cardiol"},{"issue":"7","key":"3418_CR22","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1080\/14712598.2025.2511063","volume":"25","author":"M Jha","year":"2025","unstructured":"Jha M, Agrawal SP, Maheta D, et al. Efficacy and safety of evolocumab in statin-treated patients with cardiovascular risk factors: a systematic review and meta-analysis. Expert Opin Biol Ther. 2025;25(7):749\u201359. https:\/\/doi.org\/10.1080\/14712598.2025.2511063.","journal-title":"Expert Opin Biol Ther"},{"issue":"5","key":"3418_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2024.10.017","volume":"35","author":"Z Cheng","year":"2025","unstructured":"Cheng Z, Gao M, Liu Y, et al. Safety and efficacy of inclisiran in treating hypercholesterolemia: a systemic review and meta-analysis. Nutr Metab Cardiovasc Dis. 2025;35(5):103779. https:\/\/doi.org\/10.1016\/j.numecd.2024.10.017.","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"3418_CR24","doi-asserted-by":"publisher","first-page":"28885","DOI":"10.1074\/jbc.M109.052407","volume":"284","author":"H Li","year":"2009","unstructured":"Li H, Dong B, Park SW, Lee HS, Chen W, Liu J. Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine. J Biol Chem. 2009;284:28885\u201395. https:\/\/doi.org\/10.1074\/jbc.M109.052407.","journal-title":"J Biol Chem"},{"key":"3418_CR25","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1038\/nm1135","volume":"10","author":"W Kong","year":"2004","unstructured":"Kong W, Wei J, Abidi P, et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med. 2004;10:1344\u201351. https:\/\/doi.org\/10.1038\/nm1135.","journal-title":"Nat Med"},{"issue":"10","key":"3418_CR26","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1080\/13543784.2023.2267972","volume":"32","author":"JR Burnett","year":"2023","unstructured":"Burnett JR, Hooper AJ. MK-0616: an oral PCSK9 inhibitor for hypercholesterolemia treatment. Expert Opin Investig Drugs. 2023;32(10):873\u20138. https:\/\/doi.org\/10.1080\/13543784.2023.2267972.","journal-title":"Expert Opin Investig Drugs"},{"key":"3418_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2025.120420","volume":"408","author":"S Xie","year":"2025","unstructured":"Xie S, Galimberti F, Olmastroni E, et al. Effect of lipid-lowering therapies on lipoprotein(a) levels: a comprehensive meta-analysis of randomized controlled trials. Atherosclerosis. 2025;408:120420. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2025.120420.","journal-title":"Atherosclerosis"},{"key":"3418_CR28","doi-asserted-by":"publisher","first-page":"6040","DOI":"10.3390\/jcm11206040","volume":"11","author":"HS Bhatia","year":"2022","unstructured":"Bhatia HS, Wilkinson MJ. Lipoprotein(a): evidence for role as a causal risk factor in cardiovascular disease and emerging therapies. J Clin Med. 2022;11:6040. https:\/\/doi.org\/10.3390\/jcm11206040.","journal-title":"J Clin Med"},{"key":"3418_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2025.07.021","volume":"139","author":"A Pirillo","year":"2025","unstructured":"Pirillo A, Catapano AL. Lipoprotein (a): a new target for pharmacological research and an option for treatment. Eur J Intern Med. 2025;139:106425. https:\/\/doi.org\/10.1016\/j.ejim.2025.07.021.","journal-title":"Eur J Intern Med"},{"key":"3418_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100624","volume":"29","author":"KK Ray","year":"2023","unstructured":"Ray KK, Haq I, Bilitou A, et al. Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study. Lancet Reg Health. 2023;29:100624. https:\/\/doi.org\/10.1016\/j.lanepe.2023.100624.","journal-title":"Lancet Reg Health"},{"issue":"11","key":"3418_CR31","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","volume":"28","author":"KK Ray","year":"2021","unstructured":"Ray KK, Molemans B, Schoonen WM, et al. EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study. Eur J Prev Cardiol. 2021;28(11):1279\u201389. https:\/\/doi.org\/10.1093\/eurjpc\/zwaa047.","journal-title":"Eur J Prev Cardiol"},{"issue":"11","key":"3418_CR32","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1001\/jamacardio.2017.3451","volume":"2","author":"AM Navar","year":"2017","unstructured":"Navar AM, Taylor B, Mulder H, et al. Association of prior authorization and out-of-pocket costs with patient access to PCSK9 inhibitor therapy. JAMA Cardiol. 2017;2(11):1217\u201325. https:\/\/doi.org\/10.1001\/jamacardio.2017.3451.","journal-title":"JAMA Cardiol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03418-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03418-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03418-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T09:32:04Z","timestamp":1769765524000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03418-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["3418"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03418-x","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,25]]},"assertion":[{"value":"18 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Walter Masson is an Editorial Board member of Advances in Therapy. Walter Masson was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Mart\u00edn Lobo, Gustavo Giunta, Leandro Barbagelata, and Juan P Nogueira have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}